Comprehensive Psychiatry
Volume 53, Issue 2 , Pages 130-139, February 2012

Placing symptoms in context: the role of contextual criteria in reducing false positives in Diagnostic and Statistical Manual of Mental Disorders diagnoses

  • Jerome C. Wakefield

      Affiliations

    • Silver School of Social Work, New York, NY 10003, USA
    • Department of Psychiatry, School of Medicine, New York University, New York, NY 10016, USA
    • InSPIRES (Institute for Social and Psychiatric Initiatives–Research, Education and Services), Bellevue Hospital/New York University, New York, NY 10016, USA
    • Division of Clinical Phenomenology, Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 212 932 9705.
    • ,
  • Michael B. First

      Affiliations

    • Division of Clinical Phenomenology, Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    • New York State Psychiatric Institute, New York, NY 10032, USA

published online 12 May 2011.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Dr. Wakefield has no financial relationship with commercial interests or other conflicts of interest to report. Dr. First receives royalties from books related to DSM-IV (eg, DSM-IV Guidebook) and consults to pharmaceutical companies to provide diagnostic training for clinical trials. In the past 12 months, he has consulted with Cephalon, GlaxoSmithKline, Memory Pharmaceuticals, WorldwideClinical Trials, and i3 research.

PII: S0010-440X(11)00029-0

doi:10.1016/j.comppsych.2011.03.001

Comprehensive Psychiatry
Volume 53, Issue 2 , Pages 130-139, February 2012

Article Tools